A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in Europe

First published: 25/03/2024 Last updated: 25/03/2024





Administrative details

EU PAS number		
EUPAS100000084		
Study ID		
100000084		
DARWIN EU® study		
No		
Study countries		
France		
Germany		

Italy	
Netherlands	
Spain	

Study description

The overall research questions for this study are: 1) What are the demographic, clinical, and treatment characteristics of a population of patients who initiate inebilizumab in real-world practice? 2) What are inebilizumab treatment patterns in the first 12 months following treatment initiation? 3) What is the incidence of adverse events of special interest (AESI) in the first 12 months following treatment initiation?

Specific objectives are:

- To describe demographic, clinical and treatment characteristics of patients at the time of first inebilizumab treatment
- To describe inebilizumab treatment patterns in the first 12 months following treatment initiation in terms of dosing, duration of treatment, frequency of drug discontinuation, switching, and use of add-on therapies
- To quantify the incidence of AESI, including serious infections, opportunistic infections, hepatitis B reactivations, serious infusion related reactions, and malignancies.

Analyses will be performed in the overall study population and in sub-groups of special interest: patients concomitantly receiving other immunosuppressive agents and patients aged >65 years at index date.

Study status

Planned

Research institutions and networks

Institutions

Global Database Studies, IQVIA
Czechia
Finland
Germany
☐ Slovakia
Spain
First published: 17/01/2011
Last updated: 31/07/2024
Institution Other ENCePP partner

Contact details

Study institution contact

Ana Cristina Santos PAS_registrations@iqvia.com

Study contact

PAS_registrations@iqvia.com

Primary lead investigator

Ana Cristina Santos

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 17/08/2022 Actual: 17/08/2022

Study start date

Planned: 30/04/2024

Date of final study report

Planned: 31/12/2028

Sources of funding

Pharmaceutical company and other private sector

Study protocol

HZNP-UPL-402 Protocol v2.0 clean 17Feb2023 redacted.pdf (1.08 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Data collection methods:

Secondary use of data

Study design:

A non-interventional multi-center cohort study of patients initiating inebilizumab conducted with secondary data sources in France, Germany, Italy, the Netherlands, and Spain.

Main study objective:

This study aims to characterize patients who initiate inebilizumab, describe treatment patterns and incidence of adverse events of special interest (AESI) in the first 12 months following treatment initiation.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine

UPLIZNA

Study drug International non-proprietary name (INN) or common name

INEBILIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(L04AA47) inebilizumab

inebilizumab

(L04AG10) inebilizumab

inebilizumab

Medical condition to be studied

Neuromyelitis optica spectrum disorder

Population studied

Short description of the study population

The study population will be identified in national healthcare administrative databases, claim databases and disease-specific registries and will include adult (18 years old or more at the index date) female and male patients diagnosed with NMOSD and initiating inebilizumab during the study period.

Age groups

Adult and elderly population (≥18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Système National des Données de Santé (French national health system main database)

PHARMO Data Network

The Information System for Research in Primary Care (SIDIAP)

Data source(s), other

Observatoire Français de la Sclérose en Plaques (OFSEP)

Gesetzliche Krankenversicherung (GKV)

Registro Italiano Sclerosi Multipla e Patologie Correlate (RISM)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown